| Name | Title | Contact Details |
|---|
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
Enento Group is a Nordic knowledge company that provides digital business and consumer information services in the Nordic countries. They collect and transform data into intelligence and knowledge used in interactions between people, businesses and soc...
Swiss HSM that secure the Swiss Banking Infrastructure, Blockchain and Cloud Systems. On-premise or as CloudsHSM service with built-in key-level policies for signature authorization.
Laboratory information management system software, originally named Study Director, lab animal software, web-based applications that expedite research studies.
SYSCOM is a Chantilly, VA-based company in the Software and Internet sector.